Cardiff Oncology (CRDF) Interest Coverage Ratio Growth (1y) (2012 - 2026)
Cardiff Oncology (CRDF) Interest Coverage Ratio Growth (1y) (2012 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -60.78% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -25.59% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1,170.12% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 751.68% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 99.48% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -53.46% |
| 10 | Cardiff Oncology | 60.21 Mn | 60.21 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -4,742.36% |
| Dec 31, 2025 | 87.31% |
| Sep 30, 2025 | -218.05% |
| Jun 30, 2025 | 71.07% |
| Mar 31, 2025 | -397.20% |
| Dec 31, 2024 | -308.46% |
| Sep 30, 2024 | 80.95% |
| Jun 30, 2024 | -143.05% |
| Mar 31, 2024 | 98.09% |
| Dec 31, 2023 | 99.49% |
| Sep 30, 2023 | -129.35% |
| Jun 30, 2023 | -47.83% |
| Mar 31, 2023 | -967.71% |
| Dec 31, 2022 | -21.47% |
| Sep 30, 2022 | -1,119.09% |
| Jun 30, 2022 | -222.32% |
| Mar 31, 2022 | -570.67% |
| Dec 31, 2021 | -562.88% |
| Sep 30, 2021 | 94.95% |
| Jun 30, 2021 | 94.67% |